These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 32400077)

  • 41. Structure-Based Designed Nano-Dysferlin Significantly Improves Dysferlinopathy in BLA/J Mice.
    Llanga T; Nagy N; Conatser L; Dial C; Sutton RB; Hirsch ML
    Mol Ther; 2017 Sep; 25(9):2150-2162. PubMed ID: 28629822
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel, de novo dysferlin gene mutations in a patient with Miyoshi myopathy.
    Hu YY; Lian YJ; Xu HL; Zheng YK; Li CF; Zhang JW; Yan SP
    Neurosci Lett; 2018 Jan; 664():107-109. PubMed ID: 29138090
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Exome sequencing identifies novel dysferlin mutation in a family with pauci-symptomatic heterozygous carriers.
    Jalali-Sefid-Dashti M; Nel M; Heckmann JM; Gamieldien J
    BMC Med Genet; 2018 Jun; 19(1):95. PubMed ID: 29879922
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Miyoshi Muscular Dystrophy Due to Novel Splice Site Variants in
    Bryant G; Moore SA; Nix JS; Rice G; Gokden M; Veerapandiyan A
    Child Neurol Open; 2022; 9():2329048X221140298. PubMed ID: 36419651
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phenotypic and genotypic analysis of a patient with Miyoshi myopathy caused by truncated protein.
    Zhou J; Zhou R; Feng Q; Song X; Chen X
    Gene; 2024 Jan; 893():147929. PubMed ID: 38381504
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel splicing dysferlin mutation causing myopathy with intra-familial heterogeneity.
    Rekik S; Sakka S; Romdhane SB; Amer YB; Lehkim L; Farhat N; Mahfoudh KB; Authier FJ; Dammak M; Mhiri C
    Mol Biol Rep; 2020 Aug; 47(8):5755-5761. PubMed ID: 32666437
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of a novel founder mutation in the DYSF gene causing clinical variability in the Spanish population.
    Vilchez JJ; Gallano P; Gallardo E; Lasa A; Rojas-García R; Freixas A; De Luna N; Calafell F; Sevilla T; Mayordomo F; Baiget M; Illa I
    Arch Neurol; 2005 Aug; 62(8):1256-9. PubMed ID: 16087766
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dysferlinopathies: Clinical and genetic variability.
    Ivanova A; Smirnikhina S; Lavrov A
    Clin Genet; 2022 Dec; 102(6):465-473. PubMed ID: 36029111
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dysferlinopathy in Tunisia: clinical spectrum, genetic background and prognostic profile.
    Belhassen I; Laroussi S; Sakka S; Rekik S; Lahkim L; Dammak M; Authier FJ; Mhiri C
    Neuromuscul Disord; 2023 Oct; 33(10):718-727. PubMed ID: 37716854
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Elucidation of the Genetic Cause in Dutch Limb Girdle Muscular Dystrophy Families: A 27-Year's Journey.
    Ten Dam L; de Visser M; Ginjaar IB; van Duyvenvoorde HA; van Koningsbruggen S; van der Kooi AJ
    J Neuromuscul Dis; 2021; 8(2):261-272. PubMed ID: 33386810
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recurrent, non-traumatic, non-exertional rhabdomyolysis after immunologic stimuli in a healthy adolescent female: a case report.
    Katz J; Labilloy A; Lee A
    BMC Pediatr; 2022 Aug; 22(1):515. PubMed ID: 36042458
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dysferlinopathy misdiagnosed with juvenile polymyositis in the pre-symptomatic stage of hyperCKemia: a case report and literature review.
    Contreras-Cubas C; Barajas-Olmos F; Frayre-Martínez MI; Siordia-Reyes G; Guízar-Sánchez CC; García-Ortiz H; Orozco L; Baca V
    BMC Med Genomics; 2022 Jun; 15(1):139. PubMed ID: 35725460
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Crystal structures of the human Dysferlin inner DysF domain.
    Sula A; Cole AR; Yeats C; Orengo C; Keep NH
    BMC Struct Biol; 2014 Jan; 14():3. PubMed ID: 24438169
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Analysis of DYSF gene mutations in two pedigrees affected with limb-girdle muscular dystrophy type 2B].
    Liu Z; Liao H; Zhang X; Zhang H; Liu H; Wang H; Liu S
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2018 Aug; 35(4):498-501. PubMed ID: 30098242
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Limb-Girdle Muscular Dystrophy 2B and Miyoshi Presentations of Dysferlinopathy.
    Patel NJ; Van Dyke KW; Espinoza LR
    Am J Med Sci; 2017 May; 353(5):484-491. PubMed ID: 28502335
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dual Adeno-Associated Virus 9 with Codon-Optimized DYSF Gene Promotes In Vivo Muscle Regeneration and May Decrease Inflammatory Response in Limb Girdle Muscular Dystrophy Type R2.
    Yakovlev IA; Emelin AM; Slesarenko YS; Limaev IS; Vetrova IA; Belikova LD; Grafskaia EN; Bobrovsky PA; Pokrovsky MV; Kuzubova EV; Pokrovsky VM; Lebedev PA; Bardakov SN; Isaev AA; Deev RV
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686363
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Challenges for the genetic screening in dysferlin deficiency--report of an instructive case and review of the literature.
    Gal A; Siska E; Nagy Z; Karpati G; Molnar MJ
    Clin Neuropathol; 2008; 27(5):289-94. PubMed ID: 18808059
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical and genetic analysis of Korean patients with Miyoshi myopathy: identification of three novel mutations in the DYSF gene.
    Cho HJ; Sung DH; Kim EJ; Yoon CH; Ki CS; Kim JW
    J Korean Med Sci; 2006 Aug; 21(4):724-7. PubMed ID: 16891820
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Late onset in dysferlinopathy widens the clinical spectrum.
    Klinge L; Dean AF; Kress W; Dixon P; Charlton R; Müller JS; Anderson LV; Straub V; Barresi R; Lochmüller H; Bushby K
    Neuromuscul Disord; 2008 Apr; 18(4):288-90. PubMed ID: 18396043
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.